Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Arthritis Care Res (Hoboken). 2022 Jan;74(1):16–21. doi: 10.1002/acr.24797

Table 2.

Factors associated with rehabilitation utilization in the prior 6 months or ever in the full sample and stratified by RA disease duration

Utilization in the last 6 months Utilization ever
Unadjusted model
OR (95% CI)
Adjusted model
OR (95% CI)
Unadjusted model
OR (95% CI)
Adjusted model
OR (95% CI)
Full Sample
Disease Activity (per unit increase in DAS28-CRP) 1.07 (0.94, 1.22) 1.01 (0.86, 1.19) 1.04 (0.95, 1.14) 1.03 (0.92, 1.16)
Disability (per unit increase in HAQ) 1.40 (1.12, 1.74) 1.41 (1.05, 1.88) 1.18 (1.01, 1.38) 1.09 (0.89, 1.35)
Age (per year) 1.03 (1.02, 1.05) 1.03 (1.01, 1.05) 1.03 (1.02, 1.04) 1.02 (1.01, 1.03)
BMI (per 1kg/m2) 1.02 (0.99, 1.04) 1.02 (0.99, 1.04) 1.02 (1.00, 1.03) 1.02 (1.00, 1.03)
Gender (Ref: Women) 0.91 (0.70, 1.18) 1.04 (0.78, 1.37) 0.87 (0.73, 1.04) 1.02 (0.83, 1.24)
Disease duration (per year) 1.00 (1.00, 1.00) 1.00 (1.00, 1.00) 1.01 (1.00, 1.01) 1.00 (1.00, 1.01)
Comorbidities (per increase in number) 1.18 (1.09, 1.27) 1.07 (0.98, 1.17) 1.30 (1.22, 1.39) 1.20 (1.11, 1.29)
DMARD use (Ref: yes) 1.08 (0.86, 1.36) 1.06 (0.83, 1.35) 0.94 (0.80, 1.12) 0.95 (0.79, 1.15)
Household income (Ref: <$30k) 1.02 (0.83, 1.24) 1.19 (0.94, 1.50) 0.97 (0.84, 1.12) 1.14 (0.96, 1.36)
Employed (Ref: no) 1.39 (1.12, 1.73) 1.18 (0.93, 1.52) 1.41 (1.23, 1.63) 1.21 (1.02, 1.43)
Education (Ref: > HS) 0.88 (0.74, 1.05) 0.84 (0.69, 1.02) 0.89 (0.79, 1.01) 0.88 (0.76, 1.02)
Early RA Subsample
Disease Activity (per unit increase in DAS28-CRP) 1.08 (0.88, 1.31) 1.11 (0.86, 1.43) 1.06 (0.92, 1.22) 1.10 (0.91, 1.33)
Disability (per unit increase in HAQ) 1.04 (0.75, 1.44) 1.12 (0.71, 1.77) 1.08 (0.85, 1.37) 1.08 (0.78, 1.50)
Age (per year) 1.04 (1.02, 1.07) 1.05 (1.02, 1.08) 1.04 (1.02, 1.05) 1.05 (1.03, 1.07)
BMI (per 1kg/m2) 1.01 (0.97, 1.05) 1.02 (0.98, 1.06) 1.02 (0.99, 1.04) 1.01 (0.98, 1.04)
Gender (Ref: Women) 1.14 (0.78, 1.65) 1.21 (0.80, 1.21) 0.94 (0.71, 1.26) 1.02 (0.74, 1.40)
Disease duration (per year) 0.96 (0.92, 1.01) 0.97 (0.92, 1.01) 1.03 (1.00, 1.07) 1.04 (1.01, 1.08)
Comorbidities (per increase in number) 1.06 (0.91, 1.24) 0.98 (0.82, 1.16) 1.17 (1.04, 1.31) 1.08 (0.95, 1.22)
DMARD use (Ref: yes) 0.85 (0.56, 1.28) 0.80 (0.52, 1.23) 0.76 (0.56, 1.02) 0.72 (0.52, 0.99)
Household income (Ref: <$30k) 1.21 (0.89, 1.64) 1.23 (0.83, 1.82) 1.12 (0.89, 1.40) 1.12 (0.85, 1.50)
Employed (Ref: no) 1.10 (0.81, 1.48) 1.00 (0.69, 1.45) 1.07 (0.86, 1.33) 0.91 (0.70, 1.19)
Education (Ref: > HS) 0.80 (0.60, 1.07) 0.76 (0.54, 1.08) 0.81 (0.66, 1.00) 0.76 (0.60, 0.98)
Established RA Subsample
Disease Activity (per unit increase in DAS28-CRP) 1.08 (0.90, 1.29) 0.96 (0.77, 1.19) 1.07 (0.94, 1.21) 1.00 (0.85, 1.17)
Disability (per unit increase in HAQ) 1.93 (1.41, 2.66) 1.70 (1.14, 2.52) 1.46 (1.16, 1.82) 1.14 (0.86, 1.52)
Age (per year) 1.02 (1.00, 1.04) 1.02 (0.99, 1.04) 1.02 (1.01, 1.03) 1.00 (0.99, 1.02)
BMI (per 1kg/m2) 1.02 (0.99, 1.05) 1.02 (0.99, 1.05) 1.02 (1.00, 1.04) 1.02 (0.99, 1.04)
Gender (Ref: Women) 0.76 (0.52, 1.11) 0.86 (0.57, 1.29) 0.86 (0.68, 1.09) 1.01 (0.77, 1.31)
Disease duration (per year) 1.00 (1.00, 1.01) 1.00 (1.00, 1.00) 1.00 (1.00, 1.01) 1.00 (1.00, 1.01)
Comorbidities (per increase in number) 1.22 (1.11, 1.34) 1.11 (1.00, 1.24) 1.34 (1.23, 1.45) 1.26 (1.15, 1.38)
DMARD use (Ref: yes) 1.28 (0.96, 1.70) 1.23 (0.91, 1.68) 1.17 (0.93, 1.48) 1.19 (0.92, 1.54)
Household income (Ref: <$30k) 0.91 (0.69, 1.21) 1.11 (0.81, 1.51) 0.95 (0.78, 1.15) 1.14 (0.90, 1.44)
Employed (Ref: no) 1.73 (1.21, 2.48) 1.43 (0.97, 2.10) 1.54 (1.26, 1.88) 1.40 (1.10, 1.77)
Education (Ref: > HS) 0.94 (0.75, 1.16) 0.89 (0.69, 1.14) 0.94 (0.80, 1.11) 0.95 (0.78, 1.14)

Abbreviations: BMI, body mass index; DAS28-CRP, Disease Activity Scale 28 with C-Reactive Protein; DMARD, disease-modifying anti-rheumatic drug; HAQ, Health Activity Questionnaire; HS, high school; Ref, reference